Skip to main content
NIH funding notice PAR-16-274

Serious Adverse Drug Reaction Research (R21)

Closed on September 7, 2019.

Posted
May 19, 2016
Close date
September 7, 2019
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $716,910 in first-year total cost, median $237,000.

Most frequent study sections

  1. Special Emphasis Panel[ZRG1 IDM-C (50)]3

Most frequent institutions

  1. BRIGHAM AND WOMEN'S HOSPITAL1
  2. UNIVERSITY OF CHICAGO1
  3. VANDERBILT UNIVERSITY MEDICAL CENTER1
Competing awards under PAR-16-274 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2020Investigating mechanisms of epidermal cell death in Toxic Epidermal Necrolysis1R21AI150657-01DIVITO, SHERRIE JILLBRIGHAM AND WOMEN'S HOSPITAL, MA$268,500ZRG1
2019Modeling Vincristine-Induced Severe and Persistent Neuropathy1R21CA222764-01A1DOLAN, MARY EILEENUNIVERSITY OF CHICAGO, IL$211,410ZRG1
2018Single Cell definition of pathogenic T cells in Drug-induced Stevens-Johnson-Syndrome/Toxic epidermal necrolysis1R21AI139021-01PHILLIPS, ELIZABETHVANDERBILT UNIVERSITY MEDICAL CENTER, TN$237,000ZRG1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

PAR-16-274: Serious Adverse Drug Reaction Research (R21) | ScienceDex | ConductScience